Gene · 10643
Papers3,038
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
741 to 760 of 3,038
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Proteins of mRNA Modification: Writers, Readers, and Erasers. | Annu Rev Biochem | 2023 | 37068770 | PubTator, text mining | PubMed |
| LRPPRC facilitates tumor progression and immune evasion through upregulation of m6A modification of PD-L1 mRNA in hepatocellular carcinoma. | Front Immunol | 2023 | 37063837 | PubTator, text mining | PubMed |
| Novel insights into the interplay between m6A modification and programmed cell death in cancer. | Int J Biol Sci | 2023 | 37063421 | PubTator, text mining | PubMed |
| Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer. | Cancer Res | 2023 | 37061993 | PubTator, text mining | PubMed |
| Sestrin2-mediated disassembly of stress granules dampens aerobic glycolysis to overcome glucose starvation. | Cell Death Discov | 2023 | 37059726 | PubTator, text mining | PubMed |
| Construction of an m6A-related lncRNA model for predicting prognosis and immunotherapy in patients with lung adenocarcinoma. | Medicine (Baltimore) | 2023 | 37058053 | PubTator, text mining | PubMed |
| IGF2BP3 Regulates TMA7-mediated Autophagy and Cisplatin Resistance in Laryngeal Cancer via m6A RNA Methylation. | Int J Biol Sci | 2023 | 37056932 | PubTator, text mining | PubMed |
| Passaging Primary Human Bronchial Epithelia Reduces CFTR-Mediated Fluid Transport and Alters mRNA Expression. | Cells | 2023 | 37048070 | PubTator, text mining | PubMed |
| Gelsolin: A comprehensive pan-cancer analysis of potential prognosis, diagnostic, and immune biomarkers. | Front Genet | 2023 | 37035750 | PubTator, text mining | PubMed |
| The m6A methylation landscape, molecular characterization and clinical relevance in prostate adenocarcinoma. | Front Immunol | 2023 | 37033963 | PubTator, text mining | PubMed |
| Comprehensive analyses of molecular features, prognostic values, and regulatory functionalities of m6A-modified long non-coding RNAs in lung adenocarcinoma. | Clin Epigenetics | 2023 | 37029420 | PubTator, text mining | PubMed |
| VIRMA promotes nasopharyngeal carcinoma, tumorigenesis, and metastasis by upregulation of E2F7 in an m6A-dependent manner. | J Biol Chem | 2023 | 37028765 | PubTator, text mining | PubMed |
| PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer. | Nat Commun | 2023 | 37024475 | PubTator, text mining | PubMed |
| A novel tumour enhancer function of Insulin-like growth factor II mRNA-binding protein 3 in colorectal cancer. | Cell Death Dis | 2023 | 37024466 | PubTator, text mining | PubMed |
| Effects of prenatal pesticide exposure on the fetal brain and placenta transcriptomes in a rodent model. | Toxicology | 2023 | 37019170 | PubTator, text mining | PubMed |
| Development a m6A regulators characterized by the immune cell infiltration in stomach adenocarcinoma for predicting the prognosis and immunotherapy response. | Aging (Albany NY) | 2023 | 37019148 | PubTator, text mining | PubMed |
| Aberrant RNA m6A modification in gastrointestinal malignancies: versatile regulators of cancer hallmarks and novel therapeutic opportunities. | Cell Death Dis | 2023 | 37015927 | PubTator, text mining | PubMed |
| N6-methyladenosine modifications in maternal-fetal crosstalk and gestational diseases. | Front Cell Dev Biol | 2023 | 37009476 | PubTator, text mining | PubMed |
| Epitranscriptomics in the development, functions, and disorders of cancer stem cells. | Front Oncol | 2023 | 37007137 | PubTator, text mining | PubMed |
| The role of RNA methyltransferase METTL3 in gynecologic cancers: Results and mechanisms. | Front Pharmacol | 2023 | 37007040 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10643/papers?page=38